Baxdrostat/dapagliflozin

Phase 3

AstraZeneca PLC (AZN)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Dec '26

AZNPhase 2$256.5B

Baxdrostat/dapagliflozin Phase 2 Est. Readout

Baxdrostat/dapagliflozin• Chronic Kidney Disease and Hypertension218

Dec 2026~ConfirmedSTALE

CT.gov

00%

Dec '26

AZNPhase 3$256.5B

Baxdrostat/dapagliflozin Phase 3 Est. Readout

Baxdrostat/dapagliflozin• Chronic Kidney Disease and Hypertension5,000

Dec 2026~Estimated

CT.gov

00%

Competitive Landscape

0 competitors in Chronic Kidney Disease and Hypertension

View Full Landscape

Drug Information

Target Indication

Chronic Kidney Disease and Hypertension

Clinical Trial

NCT07222917

Last updated: 2/9/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

AZN

AstraZeneca PLC

Pharmaceutical Preparations•Europe•NASDAQ

Related Pipeline

Saruparib (AZD5305)Phase 3

Ovarian Cancer

exenatide twice dailyPhase 3

Type 2 Diabetes Mellitus

AZD1152Phase 3

Acute Myeloid Leukemia

ChemotherapyPhase 3

Anticancer Treatment

Ciclesonide nasalPhase 3

Rhinitis, Allergic, Perennial

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts